Lataa...
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives to long-standing standards of care that include low-molecular-weight heparin and warfarin. The development of apixaban reflects a strategy to optimize the clinical pharmacology profile, dosing posology, tri...
Tallennettuna:
| Julkaisussa: | Ann N Y Acad Sci |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BlackWell Publishing Ltd
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4260137/ https://ncbi.nlm.nih.gov/pubmed/25377080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/nyas.12567 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|